Cardiovasc Diabetol:科学家发现糖尿病药物利拉利汀意想不到的“益处”

2017-06-06 Heather_z727 来宝网

富含脂肪和精制糖的食谱增加了全球肥胖和2型糖尿病的人数,而患有肥胖和糖尿病更年期妇女患心脏疾病的风险年龄相仿男性年龄相仿的比例更大,风险更高。一项密苏里大学医学院的研究人员发起的研究指出,糖尿病药物利拉利汀可以预防和加强超重雌性老鼠的心脏左心室,这一发现有助于人类特别是女性管理自己的心血管健康。

富含脂肪和精制糖的食谱增加了全球肥胖和2型糖尿病的人数,而患有肥胖和糖尿病更年期妇女患心脏疾病的风险年龄相仿男性年龄相仿的比例更大,风险更高。一项密苏里大学医学院的研究人员发起的研究指出,糖尿病药物利拉利汀可以预防和加强超重雌性老鼠的心脏左心室,这一发现有助于人类特别是女性管理自己的心血管健康。

研究人员表示:“在先前的研究中,我们表明,年轻的雌性老鼠食用西方饮食,高脂肪,蔗糖和高果糖的食物不仅会使体重增加,也会表现出血管硬化等症状,这与我们此次的试验结果是一致的,在我们此次研究中,我们试图了解利拉利汀对于防止心脏疾病的作用。”

利拉利汀是常规降血糖药物,在此次试验中,研究人员将实验小鼠分为两组,其中一组每日喂食正常食谱或者高脂肪的西方食谱,另一组喂食高脂肪的西方食谱,并加以低剂量的利拉利汀,试验时长为四个月,通过超声波来观察小鼠左心房的能力。

实验结果发现:“喂食西方饮食的老鼠体重增加,心脏重量增加,舒张功能不全。然而,西方饮食搭配低剂量利拉利汀的小鼠却没有出现舒张功能不全的症状,除此之外,他们氧化应激反应更少,炎症状况也更少。”

“这一发现是令人兴奋的,接下来我们将进一步研究利拉利汀对于重要蛋白质功能的影响,希望可以对心血管疾病的管理贡献一份力量。”

原始出处:

评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637774, encodeId=270d163e774cb, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 19 00:11:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802425, encodeId=5fb318024253e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Dec 17 05:11:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938702, encodeId=d8df1938e0246, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 09 00:11:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759995, encodeId=e9701e599957f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 05 05:11:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584090, encodeId=0c2e15840902c, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Jun 08 03:11:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207631, encodeId=733420e63168, content=糖尿病需要控制各种危险因素, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo529PGUCLT3kFumB79m00c6oLZ6XAtwicnaOCoicxBvIuDpFJAkSicuUiaoSZuUow3eqepHao7NzpbXUOnibZia06icXlK/0, createdBy=fa512069733, createdName=鹏鹏2017, createdTime=Wed Jun 07 08:55:46 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207348, encodeId=628320e3487c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue Jun 06 13:26:43 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207339, encodeId=82fb20e339e1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 06 13:22:30 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1637774, encodeId=270d163e774cb, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 19 00:11:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802425, encodeId=5fb318024253e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Dec 17 05:11:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938702, encodeId=d8df1938e0246, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 09 00:11:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759995, encodeId=e9701e599957f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 05 05:11:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584090, encodeId=0c2e15840902c, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Jun 08 03:11:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207631, encodeId=733420e63168, content=糖尿病需要控制各种危险因素, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo529PGUCLT3kFumB79m00c6oLZ6XAtwicnaOCoicxBvIuDpFJAkSicuUiaoSZuUow3eqepHao7NzpbXUOnibZia06icXlK/0, createdBy=fa512069733, createdName=鹏鹏2017, createdTime=Wed Jun 07 08:55:46 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207348, encodeId=628320e3487c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue Jun 06 13:26:43 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207339, encodeId=82fb20e339e1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 06 13:22:30 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1637774, encodeId=270d163e774cb, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 19 00:11:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802425, encodeId=5fb318024253e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Dec 17 05:11:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938702, encodeId=d8df1938e0246, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 09 00:11:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759995, encodeId=e9701e599957f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 05 05:11:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584090, encodeId=0c2e15840902c, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Jun 08 03:11:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207631, encodeId=733420e63168, content=糖尿病需要控制各种危险因素, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo529PGUCLT3kFumB79m00c6oLZ6XAtwicnaOCoicxBvIuDpFJAkSicuUiaoSZuUow3eqepHao7NzpbXUOnibZia06icXlK/0, createdBy=fa512069733, createdName=鹏鹏2017, createdTime=Wed Jun 07 08:55:46 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207348, encodeId=628320e3487c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue Jun 06 13:26:43 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207339, encodeId=82fb20e339e1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 06 13:22:30 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-11-09 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1637774, encodeId=270d163e774cb, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 19 00:11:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802425, encodeId=5fb318024253e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Dec 17 05:11:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938702, encodeId=d8df1938e0246, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 09 00:11:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759995, encodeId=e9701e599957f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 05 05:11:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584090, encodeId=0c2e15840902c, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Jun 08 03:11:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207631, encodeId=733420e63168, content=糖尿病需要控制各种危险因素, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo529PGUCLT3kFumB79m00c6oLZ6XAtwicnaOCoicxBvIuDpFJAkSicuUiaoSZuUow3eqepHao7NzpbXUOnibZia06icXlK/0, createdBy=fa512069733, createdName=鹏鹏2017, createdTime=Wed Jun 07 08:55:46 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207348, encodeId=628320e3487c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue Jun 06 13:26:43 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207339, encodeId=82fb20e339e1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 06 13:22:30 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1637774, encodeId=270d163e774cb, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 19 00:11:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802425, encodeId=5fb318024253e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Dec 17 05:11:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938702, encodeId=d8df1938e0246, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 09 00:11:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759995, encodeId=e9701e599957f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 05 05:11:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584090, encodeId=0c2e15840902c, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Jun 08 03:11:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207631, encodeId=733420e63168, content=糖尿病需要控制各种危险因素, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo529PGUCLT3kFumB79m00c6oLZ6XAtwicnaOCoicxBvIuDpFJAkSicuUiaoSZuUow3eqepHao7NzpbXUOnibZia06icXlK/0, createdBy=fa512069733, createdName=鹏鹏2017, createdTime=Wed Jun 07 08:55:46 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207348, encodeId=628320e3487c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue Jun 06 13:26:43 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207339, encodeId=82fb20e339e1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 06 13:22:30 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1637774, encodeId=270d163e774cb, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 19 00:11:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802425, encodeId=5fb318024253e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Dec 17 05:11:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938702, encodeId=d8df1938e0246, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 09 00:11:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759995, encodeId=e9701e599957f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 05 05:11:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584090, encodeId=0c2e15840902c, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Jun 08 03:11:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207631, encodeId=733420e63168, content=糖尿病需要控制各种危险因素, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo529PGUCLT3kFumB79m00c6oLZ6XAtwicnaOCoicxBvIuDpFJAkSicuUiaoSZuUow3eqepHao7NzpbXUOnibZia06icXlK/0, createdBy=fa512069733, createdName=鹏鹏2017, createdTime=Wed Jun 07 08:55:46 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207348, encodeId=628320e3487c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue Jun 06 13:26:43 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207339, encodeId=82fb20e339e1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 06 13:22:30 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-07 鹏鹏2017

    糖尿病需要控制各种危险因素

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1637774, encodeId=270d163e774cb, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 19 00:11:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802425, encodeId=5fb318024253e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Dec 17 05:11:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938702, encodeId=d8df1938e0246, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 09 00:11:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759995, encodeId=e9701e599957f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 05 05:11:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584090, encodeId=0c2e15840902c, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Jun 08 03:11:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207631, encodeId=733420e63168, content=糖尿病需要控制各种危险因素, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo529PGUCLT3kFumB79m00c6oLZ6XAtwicnaOCoicxBvIuDpFJAkSicuUiaoSZuUow3eqepHao7NzpbXUOnibZia06icXlK/0, createdBy=fa512069733, createdName=鹏鹏2017, createdTime=Wed Jun 07 08:55:46 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207348, encodeId=628320e3487c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue Jun 06 13:26:43 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207339, encodeId=82fb20e339e1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 06 13:22:30 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-06 lou.minghong

    学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1637774, encodeId=270d163e774cb, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 19 00:11:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802425, encodeId=5fb318024253e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Dec 17 05:11:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938702, encodeId=d8df1938e0246, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 09 00:11:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759995, encodeId=e9701e599957f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 05 05:11:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584090, encodeId=0c2e15840902c, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Jun 08 03:11:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207631, encodeId=733420e63168, content=糖尿病需要控制各种危险因素, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo529PGUCLT3kFumB79m00c6oLZ6XAtwicnaOCoicxBvIuDpFJAkSicuUiaoSZuUow3eqepHao7NzpbXUOnibZia06icXlK/0, createdBy=fa512069733, createdName=鹏鹏2017, createdTime=Wed Jun 07 08:55:46 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207348, encodeId=628320e3487c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue Jun 06 13:26:43 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207339, encodeId=82fb20e339e1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 06 13:22:30 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-06 虈亣靌

    学习了,谢谢作者分享!

    0

相关资讯

FDA顾问小组支持批准吸入型糖尿病药物Afrezza

4月1日,美国FDA顾问小组推荐批准MannKind公司的吸入型糖尿病药物Afrezza,称这款药物可能会帮助患者,特别是那些对胰岛素注射针头有恐惧心理的患者。FDA顾问小组表示,虽然Afrezza对1型糖尿病成人患者没有表现出收益,但它对更常见的2型糖尿病却是明显安全有效的。 总之,顾问小组以13比1的投票结果推荐批准这款药物用于1型糖尿病患者,一致投票支持其用于2型糖尿病患者,并补充称,这款药

糖尿病药物吡格列酮遭90亿罚单 波及国内30余家制药公司

8日晚间,因被指控隐瞒旗下糖尿病药物艾可拓(Actos)相关致癌风险,美国联邦法院陪审团对日本最大药商武田制药和美国礼来制药分别处以60亿美元和30亿美元罚款。 这一判罚也成为美国制药业历史上领到的最大一笔罚单。 资料显示,1999年进入美国市场的艾可拓(化学通用名:吡格列酮)是日本最大制药公司武田制药用于糖尿病治疗的口服用药,在多个国家,武田制药先后与辉瑞等、礼来其他制药公司采取联合推广模式

J Exp Med:浙大董辰方教授发现糖尿病药物对乳腺癌有积极作用

自中国的一组医疗团队风险一种名为 AKR1B1 的代谢酶对乳腺癌的作用。研究表示,AKR1B1 可以通过积极的反馈回路促进基底细胞型乳腺癌的发展。研究报告发表于《实验医学》杂志中,具体指出了通过代谢酶的抑制剂治疗乳腺癌的方法。

GLP-1类糖尿病药物的胰腺炎风险引起监管机构重视

两个月前,发表在《美国医学会杂志》上的一篇有关一些重磅糖尿病药物与癌症风险相关的研究论文引发出一些新的问题。一个月之前,FDA声称正在就该项研究中提及的两款糖尿病药物(默沙东的西他列汀及百时美施贵宝和阿斯利康的艾塞那肽)以及包括诺和诺德重磅炸弹级药物利拉鲁肽在内的其它药物进行审查。目前,如Pharmalot报道,一支安全监管组织对FDA收集的不良反应数据进行了分析,发现与早先的糖尿病治疗药物相比,

新研究发现:两种糖尿病药物 或有助治疗痴呆

英国一项最新研究发现,两种现有的糖尿病治疗药物能保护患痴呆症动物的脑部神经,防止病情恶化。这一研究有望为痴呆症治疗提供新思路。 早老性痴呆症是最常见的痴呆症类型,目前尚无有效疗法及针对性药物。患者脑部神经受损,会出现记忆、语言和认知障碍等症状。 英国兰开斯特大学的研究人员在新一期英国《神经药理学》杂志上报告说,他们在动物实验中,给早老性痴呆症患病早期的实验鼠服用两种糖尿病治疗药物,结果发现

泰格医药与默沙东拟达成1.49亿元糖尿病药物临床试验合同

8月31日,本土CRO公司泰格医药发布公告称,该公司与默沙东(中国)投资有限公司于31日签署捷诺维(西格列汀)上市后二型糖尿病临床试验服务合同的第一期工作订单。双方合作的整体合同金额预计为1.49亿元。由于项目需要立即开展,双方达成一致,于31日签署了第一期工作订单,第一期订单的总金额为2127.43万元。 公告称,由于该合同总金额较大,双方公司将花费较长时间商讨合同细节,整体合同签署日期待定。